Need Assistance?
  • US & Canada:
    +
  • UK: +

Tachyplesin I

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Tachyplesin I, an antimicrobial peptide originally found in the extract of hemocytes from the Japanese horseshoe crab, has antiviral activity against vesicular stomatitis virus, influenza A virus and HIV-1. It belongs to arthropodous peptide antibiotics, and can inhibit the growth of Gram-negative bacteria and positive bacteria, and form a complex with bacterial lipopolysaccharides.

Category
Functional Peptides
Catalog number
BAT-015165
CAS number
118231-04-2
Molecular Formula
C99H151N35O19S4
Molecular Weight
2263.74
Tachyplesin I
Size Price Stock Quantity
1 mg $699 In stock
IUPAC Name
(1R,4S,7S,10S,13R,18R,21S,24S,27S,30R,33S,39S,42S)-N-[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]-10-benzyl-33-[(2S)-butan-2-yl]-7,21,24,39-tetrakis(3-carbamimidamidopropyl)-13-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-27,42-bis[(4-hydroxyphenyl)methyl]-3,6,9,12,20,23,26,29,32,35,38,41,44-tridecaoxo-4-propan-2-yl-15,16,46,47-tetrathia-2,5,8,11,19,22,25,28,31,34,37,40,43-tridecazabicyclo[28.14.4]octatetracontane-18-carboxamide
Synonyms
H-Lys-Trp-Cys-Phe-Arg-Val-Cys-Tyr-Arg-Gly-Ile-Cys-Tyr-Arg-Arg-Cys-Arg-NH2 (Disulfide bridge: Cys3-Cys16, Cys7-Cys12); L-lysyl-L-tryptophyl-L-cysteinyl-L-phenylalanyl-L-arginyl-L-valyl-L-cysteinyl-L-tyrosyl-L-arginyl-glycyl-L-isoleucyl-L-cysteinyl-L-tyrosyl-L-arginyl-L-arginyl-L-cysteinyl-L-argininamide (3->16),(7->12)-bis(disulfide); Lipopolysaccharide-binding peptide; Tachyplesin I (Tachypleus tridentatus); Tachyplesin
Appearance
White Powder
Purity
95%
Sequence
KWCFRVCYRGICYRRCR-NH2 (Disulfide bridge: Cys3-Cys16, Cys7-Cys12)
Storage
Store at -20°C
Solubility
Soluble in Water
InChI
InChI=1S/C99H151N35O19S4/c1-5-53(4)78-94(153)132-75-51-157-156-50-74(91(150)127-69(43-55-28-32-58(135)33-29-55)85(144)121-64(24-14-38-114-96(105)106)81(140)119-47-76(137)133-78)131-93(152)77(52(2)3)134-84(143)67(27-17-41-117-99(111)112)124-86(145)68(42-54-18-7-6-8-19-54)126-90(149)73(130-88(147)71(125-80(139)61(101)21-11-12-36-100)45-57-46-118-62-22-10-9-20-60(57)62)49-155-154-48-72(89(148)120-63(79(102)138)23-13-37-113-95(103)104)129-83(142)66(26-16-40-116-98(109)110)122-82(141)65(25-15-39-115-97(107)108)123-87(146)70(128-92(75)151)44-56-30-34-59(136)35-31-56/h6-10,18-20,22,28-35,46,52-53,61,63-75,77-78,118,135-136H,5,11-17,21,23-27,36-45,47-51,100-101H2,1-4H3,(H2,102,138)(H,119,140)(H,120,148)(H,121,144)(H,122,141)(H,123,146)(H,124,145)(H,125,139)(H,126,149)(H,127,150)(H,128,151)(H,129,142)(H,130,147)(H,131,152)(H,132,153)(H,133,137)(H,134,143)(H4,103,104,113)(H4,105,106,114)(H4,107,108,115)(H4,109,110,116)(H4,111,112,117)/t53-,61-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,77-,78-/m0/s1
InChI Key
ZJQFYZCNRTZAIM-PMXBASNASA-N
Canonical SMILES
CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)N1)CCCNC(=N)N)CC3=CC=C(C=C3)O)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CC4=CC=C(C=C4)O)CCCNC(=N)N)CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CCCCN)N)CC7=CC=CC=C7)CCCNC(=N)N)C(C)C
1. Mechanism of tachyplesin I injury to bacterial membranes and intracellular enzymes, determined by laser confocal scanning microscopy and flow cytometry
Gang Jin,Wutai Guan,Xiaohua Jiang,Jun Hong,Jianguo Dai,Hongya Zhao Microbiol Res . 2015 Jan;170:69-77. doi: 10.1016/j.micres.2014.08.012.
Tachyplesin I is a 17 amino acid, cationic, antimicrobial peptide with a typical cyclic antiparallel β-sheet structure. Interactions of tachyplesin I with living bacteria are not well understood, although models have been used to elucidate how tachyplesin I permeabilizes membranes. There are several questions to be answered, such as (i) how does tachyplesin I kill bacteria after it penetrates the membrane and (ii) does bacterial death result from the inactivation of intracellular esterases as well as cell injury? In this study, the dynamic antibacterial processes of tachyplesin I and its interactions with Escherichia coli and Staphylococcus aureus were investigated using laser confocal scanning microscopy in combination with electron microscopy. The effects of tachyplesin I on E. coli cell membrane integrity, intracellular enzyme activity, and cell injury and death were investigated by flow cytometric analysis of cells following single- or double-staining with carboxyfluorescein diacetate or propidium iodide. The results of microscopy indicated that tachyplesin I kills bacteria by acting on the cell membrane and intracellular contents, with the cell membrane representing the primary target. Microscopy results also revealed that tachyplesin I uses different modes of action against E. coli and S. aureus. The results of flow cytometry showed that tachyplesin I caused E. coli cell death mainly by compromising cell membrane integrity and causing the inactivation of intracellular esterases. Flow cytometry also revealed dynamic changes in the different subpopulations of cells with increase in tachyplesin I concentrations. Bacteria exposed to 5 μg/mL of tachyplesin I did not die instantaneously; instead, they died gradually via a sublethal injury. However, upon exposure to 10-40 μg/mL of tachyplesin I, the bacteria died almost immediately. These results contribute to our understanding of the antibacterial mechanism employed by tachyplesin I.
2. Experimental Induction of Bacterial Resistance to the Antimicrobial Peptide Tachyplesin I and Investigation of the Resistance Mechanisms
Jianye Hu,Fei Ke,Jun Hong Antimicrob Agents Chemother . 2016 Sep 23;60(10):6067-75. doi: 10.1128/AAC.00640-16.
Tachyplesin I is a 17-amino-acid cationic antimicrobial peptide (AMP) with a typical cyclic antiparallel β-sheet structure that is a promising therapeutic for infections, tumors, and viruses. To date, no bacterial resistance to tachyplesin I has been reported. To explore the safety of tachyplesin I as an antibacterial drug for wide clinical application, we experimentally induced bacterial resistance to tachyplesin I by using two selection procedures and studied the preliminary resistance mechanisms. Aeromonas hydrophila XS91-4-1, Pseudomonas aeruginosa CGMCC1.2620, and Escherichia coli ATCC 25922 and F41 showed resistance to tachyplesin I under long-term selection pressure with continuously increasing concentrations of tachyplesin I. In addition, P. aeruginosa and E. coli exhibited resistance to tachyplesin I under UV mutagenesis selection conditions. Cell growth and colony morphology were slightly different between control strains and strains with induced resistance. Cross-resistance to tachyplesin I and antimicrobial agents (cefoperazone and amikacin) or other AMPs (pexiganan, tachyplesin III, and polyphemusin I) was observed in some resistant mutants. Previous studies showed that extracellular protease-mediated degradation of AMPs induced bacterial resistance to AMPs. Our results indicated that the resistance mechanism of P. aeruginosa was not entirely dependent on extracellular proteolytic degradation of tachyplesin I; however, tachyplesin I could induce increased proteolytic activity in P. aeruginosa Most importantly, our findings raise serious concerns about the long-term risks associated with the development and clinical use of tachyplesin I.
3. Effects of tachyplesin I on human U251 glioma stem cells
Gang Jin,Yali Han,Hong Ding,Lijun Zhang,Jianguo Dai,Jianzhang Dang Mol Med Rep . 2015 Apr;11(4):2953-8. doi: 10.3892/mmr.2014.3021.
Glioblastoma, is one of the most malignant types of intracranial tumor with complex progressive cellular and underlying molecular events. The use of glioma stem cells (GSCs) offers a promising strategy for tumor therapy in the future. Tachyplesin I has been demonstrated to have potential anticancer activity and was first observed in leukocytes. In the present study, the GSC subset was isolated from U251 glioma cells and tachyplesin I was assessed for antitumor activity. As a result, the U251 cells exhibited certain GSC phenotypes, including the expression of stem cell biomarkers CD133 and nestin, when transferred into stem cell culture conditions. The GSCs were grown in an adherent manner in a medium containing serum, while the U251 glioma cells were suspended and cultured in serum‑free medium. Tachyplesin I damaged the structure of GSC and inhibited the culture of GSC spheres in a time and dose‑dependent manner. When tachyplesin I was administered at a concentration of 10‑40 µg/ml, GSC differentiation was induced. GSCs treated with a low dose of tachyplesin I disrupted the plasma membrane and led to a loss of cytoplasmic organelles. These findings indicated that tachyplesin I had an effect on inhibiting tumor stem cells and demonstrated that tachyplesin I inhibited GSCs by disrupting the plasma membranes and inducing GSC differentiation.
4. Anti-infective biomaterials with surface-decorated tachyplesin I
Jing Hou,Dong Wang,Xiao-Bin Liu,Jun-Yu Chen,Kam W Leong,Hua Xiang,Qiong Xue,Yeh-Hsing Lao,Zhen-Qiang Zuo,Yuan-Yuan Bei,Jing Han,Lin-Ping Wu,Xue-Fei Wu Biomaterials . 2018 Sep;178:351-362. doi: 10.1016/j.biomaterials.2018.05.008.
Implants decorated with antimicrobial peptides (AMPs) can prevent infection and reduce the risk of creating antibiotic resistance. Yet the restricted mobility of surficial AMP often compromises its activity. Here, we report a simple but effective strategy to allow a more flexible display of AMP on the biomaterial surface and demonstrate its efficacy for wound healing. The AMP, tachyplesin I (Tac), is tagged with the polyhydroxyalkanoate-granule-associated protein (PhaP) and immobilized on haloarchaea-produced poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBHV) via hydrophobic interaction. The PhaP-Tac coating effectively inhibits the growth of both Gram-negative and Gram-positive bacteria. It also increases the surface hydrophilicity to improve fibroblast proliferation in vitro, and accelerates wound healing by decreasing bacterial counts to below 105CFU per gram of tissue in a deep-wound mouse model in vivo. Taken together, these findings demonstrate an effective strategy to realize the full potential of AMPs in imparting implants with an anti-microbial activity that is localized and potent.
Online Inquiry
Verification code
Inquiry Basket